HDAC-inhibition led to tumor growth arrest, accompanied by increased levels of cyclin E in leukemia and lung cancer cells [26,27], decreased cyclin E levels in breast cancer [28], whereas cyclin E was not changed in bladder cancer [29]. Here, HDAC9 is linked to breast carcinoma.